Drotrecogin alfa (activated) in severe sepsis.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  New England Journal of Medicine

• Publication date

  2006-01-05

• Fields of study

  Medicine

• Identifiers
  PMID 16395834
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Incidence of Sepsis-Induced Coagulopathy (INSIC) Trial: Study Protocol of a Combined Retrospective and Prospective, Multicenter, International, Cross-Sectional, Longitudinal, and Epidemiological Observational Trial

  2025cites this paper
• An ADAM-10 dependent EPCR shedding links meningococcal interaction with endothelial cells to purpura fulminans

  2018cites this paper
• Treatable traits and therapeutic targets: Goals for systems biology in infectious disease

  2017cites this paper
• Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failure

  2016cites this paper
• Oesophageal Doppler monitoring, doubt and equipoise: evidence based medicine means change

  2013cites this paper
• Recombinant activated protein C usage in Scotland: a comparison with published guidelines and a survey of attitudes *

  2012cites this paper
• An update on activated protein C (xigris) in the management of sepsis.

  2010cites this paper
• Microparticle-associated endothelial protein C receptor and the induction of cytoprotective and anti-inflammatory effects

  2009cites this paper
• Rapidly fatal bacteremic pneumonia caused by Klebsiella pneumoniae with K1 hypermucoviscosity phenotype in a previously healthy young man receiving levofloxacin treatment.

  2009cites this paper
• How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design

  2008cites this paper
• The efficacy of oral treatment with pramiconazole in tinea pedis and tinea cruris/corporis: two exploratory phase IIa trials

  2008cites this paper
• Generalized pustular psoriasis and cryptogenic organizing pneumonia

  2008cites this paper
• Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice

  2008cites this paper
• Why Are Clinicians Not Embracing the Results from Pivotal Clinical Trials in Severe Sepsis? A Bayesian Analysis

  2008cites this paper
• Activated protein C in sepsis: the promise of nonanticoagulant activated protein C

  2008cites this paper
• Medical Guidelines and Performance Measures: The Need to Keep Them Free of Industry Influence

  2008cites this paper
• LEVELS OF PROTEIN C ACTIVITY AND CLINICAL FACTORS IN EARLY PHASE OF PEDIATRIC SEPTIC SHOCK MAY BE ASSOCIATED WITH THE RISK OF DEATH

  2007cites this paper
• NICE Technology Appraisal No 84

  2006cites this paper
• ▼Drotrecogin alfa (activated) for severe sepsis

  2006cites this paper
• Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?

  2006cites this paper
• De lutilisation de la protine C-active dans le choc septique

  2006cites this paper
• Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom

  2006cites this paper
• Signal transduction induced by activated protein C: no role in protection against sepsis?

  2006cites this paper
• Drotrecogin alfa (activated) in the treatment of severe sepsis

  2006cites this paper
• Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom*

  2005cites this paper
• Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress Growing Insights into the Potential Benefits and Risks of Activated Protein C Administration in Sepsis: a Review of Preclinical and Clinical Studies

  year unknowncites this paper